Abstract
Full Title: Triple Analysis: Decoding Big Pharma' s R&D Strategy In Oncology
and Special Focus on Breast and Prostate Cancer
In this triple analysis report BioSeeker Group has analyzed three major and
intertwined areas of Decoding Big Pharma' s R&D Strategy in Oncology, Breast-
and Prostate cancer, which are all subjects to an extensive number of
innovative drug candidates. This extensive 440+ pages report compiles and
analyzes Deals and alliances, Drug targets, Compound types, Targeted therapy
areas, and Selection of cancer indications among the five major pharmaceutical
companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline,
Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their
respective partners they have more than 250 drugs for the treatment of cancer.
In other words, their collective R&D capacity and presence is solid enough to
set trends for the entire field of oncology drug development. Beyond trends,
all five are fiercely defining their competitive edge and advantage in
oncology and that is what this report is about.
The collective force of the above research and analysis ' decodes' these five
big pharma R&D efforts into strategy revealing and gap filing presentations.
Enough to fuel and sustain comparative benchmarking, peer group surveillance,
and partnership decisions.
The report further give an in depth analysis in two important key oncology
areas; Breast- and Prostate cancer . And provide a framework but also a
careful identification and evaluation of drug candidates, technologies and
competitors.
Decoding Big Pharma' s R&D Strategy in Oncology in numbers:
- Includes references to more than 250 drugs and 600 clinical/preclinical
trials
- Addresses the competitive situation on more than 80 different cancer
indications, including supportive care indications
- Special focus on Angiogenesis-, Antibody-, Apoptosis-, Protein kinase
inhibitor- and Vaccine drugs for the treatment of cancer
- The included competitive landscape between the five big pharma includes
more than 200 companies related to cancer drug development
- Last five years of deals and alliances in oncology, including almost a
hundred different key deals and alliances
- Target analysis of 119 drug targets in oncology, including molecular
function of target, target localization, type of compound for targeting,
targets affecting signaling pathways etc
- Drug compound analysis by cancer indications
In breast cancer we have identified 170 drug candidates in clinical stage of
development and more than 100 companies are involved in the development of
these drugs. As a treatment for breast cancer hormone modifying therapies
together with different chemotherapeutic schedules have been of highest
interest during the last years of progress. A vast amount of new clinical
research data has emerged and several new clinical trials have been initiated
and others generated new results. Protein kinase inhibitors and epothilones
have generated substantial amount of new research data in this field. But,
other strategies seem not successful and we are still waiting new information
regarding their progress.
In prostate cancer we have identified 127 drug candidates in phase II or III
stage of development and more than 85 companies are involved in the
development of these drugs. Two of the most successful strategies are
apoptosis inducers and cell based vaccines. Three out of 10 late stage
candidates are apoptosis inducers. Cell based vaccines has been tried for some
time but has so far failed to generate substantial improvements.
Breast and Prostate Cancer Highlights
- Thorough examination of status and impact of several novel drugs in
development
- Discussion of the challenges in current and future treatment strategies
- Anticancer pipeline of most companies in the field
Key reasons to read this report
- This report serves as a serious reference for professionals interested in
the development of oncology drug targets and selection/validation of targeting
strategies.
- Explore the strengths and weaknesses associated with compounds in clinical
development. Scientific rationale for most novel therapeutics in breast- and
prostate cancer R&D, and the results of clinical trials to date
- Gain insight into the current challenges and commercial opportunities
associated with breast- and prostate cancer therapy
View Cart
